Medtronic has initiated an Investigation Device Exemption study for the assessment of the efficacy and safety of the Abre Venous Self-expanding Stent System intended to treat Deep Lymphocytic Diseases in order to establish its effectiveness and safety. It is likely that this study will be conducted at 35 locations across the United States and Europe, involving about 200 subjects.
IVASC, an Italian medical device company, completed a EUR 1.8 million Series A investment in April 2022 for the launch of its VELEX product. VELEX, which received CE Mark in May 2021, is a device that can be used to treat CVI and varicose veins with a procedure called Empty Vein Ablation (EVA).
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4936
Published Date: May 04, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The major factors driving the growth of the market are increasing varicose vein global burden, and surging preference for minimally invasive treatment procedures.
The market size of varicose vein treatment is anticipated to attain a CAGR of 9.9% over the forecast period, i.e., 2023-2035.
The major players in the market are Candela Medical, Medtronic PLC, Boston Scientific, El. En SpA Group and others.
The ablation devices segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.